Beijing Chunlizhengda Medical Instruments 9M revenue falls 17%

What happened

Beijing Chunlizhengda Medical Instruments reported a 17% year-on-year fall in unaudited nine-month revenue. Net profit attributable to shareholders fell 1.6% year on year. The company gave no specific financial guidance for future quarters or the full year.

Confirmed

Global impact / market context

Lower revenue means fewer sales to cover fixed costs, but falling selling, administrative and research spending plus smaller write-downs of assets cushioned the profit hit. For a device maker, weaker cash collection from customers also reduces the cash available to fund daily operations and product development.

Analyst inference

The only available analyst rating is strong buy, and the median 12-month price target of HK$14.90 sits far above the HK$7.39 close on October 30. The stock trades at 13 times next 12-month earnings versus 15 three months ago, a cheaper multiple that may reflect weaker results.

Analyst inference

What to watch

1. Watch whether operating cash flow, which fell 32.7% on lower cash collections and bill-settlement timing, recovers, because weaker cash intake can limit spending on research and daily operations. Confirmed
2. Management could be asked to provide revenue and profit guidance in future updates, since the press release gave no specific outlook and investors lack a company forecast for coming quarters. Proposed
3. Watch research and development spending after cuts helped offset the revenue decline; continued restraint may support near-term profit but could slow the launch of new medical devices. Analyst inference

Evidence

• Original source link unavailable